Evidence map›Paper›PMID 25320178›Full record

ArticleCancer research2014

The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.

Yi-Ping Fu, Indu Kohaar, Lee E Moore, Petra Lenz, Jonine D Figueroa, Wei Tang, Patricia Porter-Gill, Nilanjan Chatterjee, Alexandra Scott-Johnson, Montserrat Garcia-Closas and 89 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Bioinformatic-based mechanism identification ofJournal of gastrointestinal oncology · 2022
    Article
  9. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.Journal of experimental & clinical cancer research : CR · 2019
    Article
  10. Motor Neuron and Pancreas Homeobox 1 (MNX1) Is Involved in Promoting Squamous Cervical Cancer Proliferation via Regulating Cyclin E.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Bladder Cancer Genetic Susceptibility. A Systematic Review.Bladder cancer (Amsterdam, Netherlands) · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

99 authors at 1 institution in 1 country.

Yi-Ping FuLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Indu KohaarLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Lee E MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Petra LenzClinical Research Directorate/Clinical Monitoring Research Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Wei TangLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Patricia Porter-GillLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Nilanjan ChatterjeeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Alexandra Scott-JohnsonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Montserrat Garcia-ClosasDivision of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
Brian MuchmoreLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Dalsu BarisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ashley PaquinLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kris YlayaLaboratory of Pathology, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Molly SchwennMaine Cancer Registry, Augusta, Maine.
Andrea B ApoloGenitourinary Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Margaret R KaragasGeisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
McAnthony TarwayLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Alison JohnsonVermont Cancer Registry, Burlington, Vermont.
Adam MumyLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Alan SchnedGeisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Liliana GuedezRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Michael A JonesDepartment of Pathology and Laboratory Medicine, Maine Medical Center, Portland, Maine.
Masatoshi KidaDepartment of Pathology, University of Vermont College of Medicine, Burlington, Vermont.
G M Monawar HosainNew Hampshire State Cancer Registry, Concord, New Hampshire.
Nuria MalatsSpanish National Cancer Research Centre, Madrid, Spain.
Manolis KogevinasCentre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. National School of Public Health, Athens, Greece. CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain.
Adonina TardonCIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
Consol SerraCIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. Universitat Pompeu Fabra, Barcelona, Spain.
Alfredo CarratoRamón y Cajal Hospital, Madrid, Spain.
Reina Garcia-ClosasUnidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain.
Josep LloretaHospital del Mar-IMIM, Univesitat Pompeu Fabra, Barcelona, Spain.
Xifeng WuDepartment of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Mark PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Gerald L AndrioleDivision of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri.
Robert L GrubbDivision of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri.
Amanda BlackDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Maria T LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Paolo VineisSchool of Public Health, Imperial College London, London, United Kingdom. Human Genetics Foundation (HuGeF), Torino, Italy.
Afshan SiddiqSchool of Public Health, Imperial College London, London, United Kingdom.
H Bas Bueno-de-MesquitaNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands. Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom. Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Dimitrios TrichopoulosDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. Hellenic Health Foundation, Athens, Greece.
Börje LjungbergDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Gianluca SeveriHuman Genetics Foundation (HuGeF), Torino, Italy. Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia. Centre for Epidemiology and Biostatistics, University of Melbourne, Australia.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Samfundet Folkhälsan, Helsinki, Finland.
Vittorio KroghFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Miren DorronsoroPublic Health Division of Gipuzkoa, Basque Regional Health Department and Ciberesp-Biodonostia, San Sebastian, Spain.
Ruth C TravisCancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elio RiboliSchool of Public Health, Imperial College London, London, United Kingdom.
Jennifer PrescottChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Constance ChenProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Immaculata De VivoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Edward GovannucciDepartment of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
David HunterProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Peter KraftProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Sara LindstromProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, Georgia.
Eric J JacobsEpidemiology Research Program, American Cancer Society, Atlanta, Georgia.
W Ryan DiverEpidemiology Research Program, American Cancer Society, Atlanta, Georgia.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jarmo VirtamoNational Institute for Health and Welfare, Helsinki, Finland.
Charles KooperbergFred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.
Chancellor HohenseeFred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.
Rebecca J RodaboughFred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.
Victoria K CortessisDepartment of Obstetrics and Gynecology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. Department of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
David V ContiDepartment of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Manuela Gago-DominguezGenomic Medicine Group, Galician Foundation of Genomic Medicine, Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
Mariana C SternDepartment of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Malcolm C PikeDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
David Van Den BergDepartment of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Jian-Min YuanUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Olivier CussenotAP-HP, Hopital Tenon, GHU-Est, Department of Urology, Paris, France. Centre de Recherche sur les Pathologies Prostatiques, Paris, France. UPMC Univ Paris 06, ONCOTYPE-URO, Paris, France.
Geraldine Cancel-TassinCentre de Recherche sur les Pathologies Prostatiques, Paris, France. UPMC Univ Paris 06, ONCOTYPE-URO, Paris, France.
Morgan RoupretCentre de Recherche sur les Pathologies Prostatiques, Paris, France. UPMC Univ Paris 06, ONCOTYPE-URO, Paris, France. AP-HP, Hopital Pitie-Salpetriere, GHU-Est, Departments of Urology and Pathology, Paris, France.
Eva ComperatCentre de Recherche sur les Pathologies Prostatiques, Paris, France. UPMC Univ Paris 06, ONCOTYPE-URO, Paris, France. AP-HP, Hopital Pitie-Salpetriere, GHU-Est, Departments of Urology and Pathology, Paris, France.
Stefano PorruDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Angela CartaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Sofia PavanelloDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.
Cecilia AriciDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Giuseppe MastrangeloDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.
H Barton GrossmanDepartment of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Zhaoming WangCancer Genomics Research Laboratory, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Xiang DengCancer Genomics Research Laboratory, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Charles C ChungCancer Genomics Research Laboratory, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Amy HutchinsonCancer Genomics Research Laboratory, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Laurie BurdetteCancer Genomics Research Laboratory, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
William WheelerInformation Management Services, Rockville, Maryland.
Joseph FraumeniDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stephen M HewittLaboratory of Pathology, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Debra T SilvermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. prokuninal@mail.nih.gov.
Institute of Cancer Research · GB

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Laboratory of Translational GenomicsZIACP010201 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI PROKUNINA-OLSSON, LIUDMILA · 2010 to 2025
$91.2M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
British Heart FoundationCancer Research UK 16491CCR NIH HHS N01 RC037004CCR NIH HHS N01-RC-45035Department of HealthIntramural NIH HHS Z99 CA999999Medical Research CouncilNCI NIH HHS 1P01CA86871NCI NIH HHS 1R01CA114665NCI NIH HHS CA055075NCI NIH HHS CA082838NCI NIH HHS CA34627NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201000006CNCI NIH HHS N01 CN045035NCI NIH HHS N01 CN045165NCI NIH HHS N02 CP001037NCI NIH HHS N02-CP-01037NCI NIH HHS N02 CP011015NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA086871NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA091846NCI NIH HHS R01 CA034627NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA057494NCI NIH HHS R01 CA065726NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA082838NCI NIH HHS R01 CA089715NCI NIH HHS R01-CA089715NCI NIH HHS R01 CA114665NCI NIH HHS R01CA114665NCI NIH HHS R01 CA49449NCI NIH HHS R01CA65726NCI NIH HHS R01 CA67262NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA176726NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01HG004438NHGRI NIH HHS U01 HG004446NHGRI NIH HHS U01HG004446NHLBI NIH HHS HHSN268200782096CNHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS R01HL091172-01NIA NIH HHS HHSN271201100004CNIGMS NIH HHS T32 GM007814Wellcome TrustWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004CWorld Health Organization 001
6 · The paper itself

Abstract

A genome-wide association study (GWAS) of bladder cancer identified a genetic marker rs8102137 within the 19q12 region as a novel susceptibility variant. This marker is located upstream of the CCNE1 gene, which encodes cyclin E, a cell-cycle protein. We performed genetic fine-mapping analysis of the CCNE1 region using data from two bladder cancer GWAS (5,942 cases and 10,857 controls). We found that the original GWAS marker rs8102137 represents a group of 47 linked SNPs (with r(2) ≥ 0.7) associated with increased bladder cancer risk. From this group, we selected a functional promoter variant rs7257330, which showed strong allele-specific binding of nuclear proteins in several cell lines. In both GWASs, rs7257330 was associated only with aggressive bladder cancer, with a combined per-allele OR = 1.18 [95% confidence interval (CI), 1.09-1.27, P = 4.67 × 10(-5)] versus OR = 1.01 (95% CI, 0.93-1.10, P = 0.79) for nonaggressive disease, with P = 0.0015 for case-only analysis. Cyclin E protein expression analyzed in 265 bladder tumors was increased in aggressive tumors (P = 0.013) and, independently, with each rs7257330-A risk allele (P(trend) = 0.024). Overexpression of recombinant cyclin E in cell lines caused significant acceleration of cell cycle. In conclusion, we defined the 19q12 signal as the first GWAS signal specific for aggressive bladder cancer. Molecular mechanisms of this genetic association may be related to cyclin E overexpression and alteration of cell cycle in carriers of CCNE1 risk variants. In combination with established bladder cancer risk factors and other somatic and germline genetic markers, the CCNE1 variants could be useful for inclusion into bladder cancer risk prediction models.

Indexed as

Case-Control StudiesChromosomes, Human, Pair 19Cyclin EGene ExpressionGene FrequencyGenome-Wide Association StudyHaplotypesHeLa CellsHumansOncogene ProteinsPolymorphism, Single NucleotideUrinary BladderUrinary Bladder NeoplasmsCCNE1 protein, humanCyclin EOncogene Proteins

Identifiers

PMID25320178
PMCPMC4203382
OpenAlexW2160092994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.